home / stock / cytr / cytr news

CYTR News and Press, CytRx Corporation From 08/12/21

Stock Information
Company Name: CytRx Corporation
Stock Symbol: CYTR
Market: NASDAQ
Website: cytrx.com
Menu
CYTR CYTR Quote CYTR Short CYTR News CYTR Articles CYTR Message Board
Get CYTR Alerts

News, Short Squeeze, Breakout and More Instantly...
CYTR - CytRx Comments on Quarterly Results and Recent Strategic Initiatives

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the second quarter ended June ...
CYTR - CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders

New Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categor...

CYTR - CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022

ImmunityBio’s Receipt of U.S. Patent for Novel Immunotherapy, NANT Cancer Vaccine, Being Studied in Multiple Clinical Trials CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and d...

CYTR - CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor

CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced the closing of its previously announced sale of its securities...
CYTR - CytRx inks securities purchase agreement for $10M

CytRx (CYTR) has entered into a securities purchase agreement with healthcare-focused institutional investor for aggregate gross proceeds of ~$10M.Under the terms of the agreement, CytRx has agreed to sell 2M shares of common stock at $0.88/share for gross proceeds of ~$1.76M in a registered ...

CYTR - CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor

CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has entered into a securities purchase agreement (the ...

CYTR - CytRx Comments on Orphazyme's Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S’s (NASDAQ: ORPH) ("Orphazyme") recently announced 24-month interim re...
CYTR - Orphazyme: Game Over, Man

Hopes were high for Orphazyme’s arimoclomol following FDA’s controversial decision on Alzheimer’s therapy aducanumab. However, the agency has rejected arimoclomol, and the company released weak guidance for 2021. Orphazyme needs to tap the equity markets relat...

CYTR - CytRx Notes Orphazyme's Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced it has received a Complete Response Let...

CYTR - Orphazyme plunges as hype-driven rally unravels after FDA decision

JHVEPhoto/iStock Editorial via Getty Images Danish biotech Orphazyme ([[ORPH]] -43.0%) has extended the pre-market losses after the FDA decision not to grant the approval for Arimoclomol the company’s experimental therapy for rare genetic disease Niemann-Pick Disease Type C ((NPC)). Cy...
Previous 10 Next 10